L G E M Razenberg1, Y R B M van Gestel2, G-J Creemers3, V J Verwaal4, V E P P Lemmens5, I H J T de Hingh6. 1. Department of Oncology, Catharina Hospital, Eindhoven, The Netherlands; Eindhoven Cancer Registry/Netherlands Comprehensive Cancer Organisation (IKNL), Eindhoven, The Netherlands. 2. Eindhoven Cancer Registry/Netherlands Comprehensive Cancer Organisation (IKNL), Eindhoven, The Netherlands. 3. Department of Oncology, Catharina Hospital, Eindhoven, The Netherlands. 4. Department of Surgical Oncology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 5. Eindhoven Cancer Registry/Netherlands Comprehensive Cancer Organisation (IKNL), Eindhoven, The Netherlands; Department of Public Health, Erasmus MC University Medical Centre, Rotterdam, The Netherlands. 6. Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands. Electronic address: ignace.d.hingh@catharinaziekenhuis.nl.
Abstract
BACKGROUND: Population-based data on the percentage of colorectal cancer (CRC) patients with synchronous peritoneal carcinomatosis (PC) being treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are currently lacking. The current population-based study describes trends in the use of CRS-HIPEC in the Netherlands, one of the first countries where CRS and HIPEC was introduced. METHODS: All patients diagnosed with synchronous PC of CRC between 2005 and 2012 were extracted from the Netherlands Cancer Registry (n = 4623). Patients with primary appendiceal cancer were excluded resulting in a study population of 4430 patients. Trends in the use of CRS-HIPEC over time were analyzed by means of a Cochrane-Armitage trend test. Survival proportions were calculated as the time between diagnosis and date of death or last follow-up (January 2014). RESULTS: Of the total 4430 patients with synchronous PC, 297 (6.4%) underwent treatment with CRS-HIPEC. The proportion of colorectal PC patients receiving CRS-HIPEC increased significantly over time from 3.6% in 2005-2006 to 9.7% in 2011-2012 (p < 0.0001). Overall median survival (MS) for patients treated with CRS-HIPEC was 32.3 months, whereas MS rates were respectively 12.6, 6.1 and 1.5 for months palliative chemotherapy with/without surgery, palliative surgery and best supportive care. CONCLUSION: The proportion of patients diagnosed with synchronous PC from CRC treated with CRS-HIPEC has increased significantly over time and currently almost 10% of PC patients are treated with CRS-HIPEC. Median survival in this population based group is 32.3 months.
BACKGROUND: Population-based data on the percentage of colorectal cancer (CRC) patients with synchronous peritoneal carcinomatosis (PC) being treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are currently lacking. The current population-based study describes trends in the use of CRS-HIPEC in the Netherlands, one of the first countries where CRS and HIPEC was introduced. METHODS: All patients diagnosed with synchronous PC of CRC between 2005 and 2012 were extracted from the Netherlands Cancer Registry (n = 4623). Patients with primary appendiceal cancer were excluded resulting in a study population of 4430 patients. Trends in the use of CRS-HIPEC over time were analyzed by means of a Cochrane-Armitage trend test. Survival proportions were calculated as the time between diagnosis and date of death or last follow-up (January 2014). RESULTS: Of the total 4430 patients with synchronous PC, 297 (6.4%) underwent treatment with CRS-HIPEC. The proportion of colorectal PCpatients receiving CRS-HIPEC increased significantly over time from 3.6% in 2005-2006 to 9.7% in 2011-2012 (p < 0.0001). Overall median survival (MS) for patients treated with CRS-HIPEC was 32.3 months, whereas MS rates were respectively 12.6, 6.1 and 1.5 for months palliative chemotherapy with/without surgery, palliative surgery and best supportive care. CONCLUSION: The proportion of patients diagnosed with synchronous PC from CRC treated with CRS-HIPEC has increased significantly over time and currently almost 10% of PC patients are treated with CRS-HIPEC. Median survival in this population based group is 32.3 months.
Authors: Koen P Rovers; Checca Bakkers; Felice N van Erning; Jacobus W A Burger; Simon W Nienhuijs; Geert A A M Simkens; Geert-Jan M Creemers; Patrick H J Hemmer; Cornelis J A Punt; Valery E P P Lemmens; Pieter J Tanis; Ignace H J T de Hingh Journal: JAMA Oncol Date: 2020-08-13 Impact factor: 31.777
Authors: D M Le; S Ahmed; S Ahmed; B Brunet; J Davies; C Doll; M Ferguson; N Ginther; V Gordon; T Hamilton; P Hebbard; R Helewa; C A Kim; R Lee-Ying; H Lim; J M Loree; J P McGhie; K Mulder; J Park; D Renouf; R P W Wong; A Zaidi; T Asif Journal: Curr Oncol Date: 2019-12-01 Impact factor: 3.677
Authors: Geert A Simkens; Vic J Verwaal; Valery E Lemmens; Harm J Rutten; Ignace H de Hingh Journal: Medicine (Baltimore) Date: 2016-10 Impact factor: 1.889
Authors: Tanja Grimmig; Eva-Maria Moll; Kerstin Kloos; Rebecca Thumm; Romana Moench; Simone Callies; Jennifer Kreckel; Malte Vetterlein; Joerg Pelz; Buelent Polat; Sudipta Tripathi; Roberta Rehder; Carmen M Ribas; Anil Chandraker; Christoph-T Germer; Ana Maria Waaga-Gasser; Martin Gasser Journal: Cancer Growth Metastasis Date: 2017-09-18
Authors: Kurinchi Gurusamy; Claire L Vale; Elena Pizzo; R Bhanot; Brian R Davidson; Tim Mould; Muntzer Mughal; Mark Saunders; Omer Aziz; Sarah O'Dwyer Journal: BMJ Open Date: 2020-05-12 Impact factor: 2.692